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Background: The need to promote novel drug development for advanced biliary tract cancer (ABTC) has emphasised the
importance of determining whether various efficacy end points can act as surrogates for overall survival (OS).
Methods:We conducted a literature search of randomised trials of first-line chemotherapy for ABTC and investigated correlations
between efficacy end points and OS using weighted linear regression analysis. The ratios of the median OS, median progression-
free survival (PFS), response rate, and disease control rate in each trial were used to summarise treatment effects. The surrogate
threshold effect (STE), which was the minimum treatment effect on PFS required to predict a non-zero treatment effect on OS, was
calculated.
Results: Seventeen randomised trials with 36 treatment arms were identified, and a sample size of 2148 patients with 19 paired
arms was analysed. The strongest correlation between all evaluated efficacy end points was observed between median OS and
median PFS ratios (r2¼ 0.66). In trials with gemcitabine-containing therapies and targeted agents, the r2-values were 0.78. The STE
was estimated at 0.83 for all trials and 0.81 for trials with gemcitabine-containing therapies, and was not calculated for trials with
targeted agents.
Conclusions: The median PFS ratio correlated well with the median OS ratio, and may be useful for planning a clinical trial for
novel drug development.
Biliary tract cancer is a rare disease that includes intrahepatic and
extrahepatic cholangiocarcinoma, gallbladder carcinoma, and
ampullary carcinoma, and patients with unresectable or recurrent
forms of these cancers are generally treated with palliative
chemotherapy. The key anti-cancer drug for advanced biliary tract
cancer (ABTC) is gemcitabine. Recently, gemcitabineþ cisplatin
(GP) has been recognised as a standard first-line treatment for
ABTC following the results of a randomised phase III trial (ABC-
02 trial) that compared GP with gemcitabine alone (Valle et al,
2010). Despite the favourable outcome of that trial, the prognosis
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of patients with ABTC remains poor, with a median survival time
ofB12 months. Accordingly, new drugs or combination therapies
should be studied with the intent to improve survival.
Although overall survival (OS) is considered a gold-standard
hard end point of trials assessing oncologic drugs, a validated
shorter-term surrogate end point for OS would reduce the sample
size, cost, and trial duration needed to demonstrate the benefit of a
novel drug. A previous pooled analysis of 104 clinical trials for
ABTC prior to establishing GP as a standard chemotherapy
regimen was conducted to identify superior treatment regimens
(Eckel and Schmid, 2007). This study identified the time to
progression (TTP) was significantly associated with OS as a
secondary objective. However, the analysis included mostly small
sample size and non-randomised trials. In the present study, we
investigated various efficacy end points as potential surrogates for
OS in studies of first-line chemotherapy for ABTC in a limited pool
of randomised trials to allow the accurate estimation of treatment
effects.
MATERIALS AND METHODS
Registration. This study is registered in the PROSPERO database
(CRD42014014526) and was conducted according to the Preferred
Reporting Items for Systemic Reviews and Meta-Analysis
(PRISMA) statement.
Selection of eligible studies. Eligible studies were randomised
phase II and III trials involving patients with ABTC who were
treated with first-line chemotherapy. Studies involving the
following were excluded: hepatic infusional chemotherapy; combi-
nation therapy with a local control therapy such as radiotherapy,
surgery or photodynamic therapy, or non-English language
reports.
Search strategy. Trials involving ABTC that were published up to
February 2015 were identified through a systemic search of the
PubMed database, using the keywords ‘biliary tract neoplasms’
OR ‘bile duct neoplasms’ OR ‘gallbladder neoplasms’ OR
‘cholangiocarcinoma’ (all fields) AND ‘chemotherapy’ (all fields)
AND ‘clinical trial’ (ptyp). A manual search was also performed for
abstracts presented at the annual meetings of the American Society
of Clinical Oncology (ASCO), Gastrointestinal Cancers Sympo-
sium, European Society of Medical Oncology, and World Congress
of Gastrointestinal Cancer up to February 2015.
Data extraction. Two authors (TM and YY) independently
extracted information from the selected literature using predefined
data abstract forms. The following details were extracted: published
or presented year, number of enroled patients, primary end
point, chemotherapy regimen, and tumour location (intrahepatic
cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder
carcinoma, and ampullary carcinoma). The various efficacy
parameters assessed as potential surrogate end points for and
evaluated for correlations with OS were progression-free survival
(PFS; defined as the time to initial progression or death by any
cause), TTP (defined as the time to initial progression or cancer-
related death), response rate (RR; defined as the rate of complete
and partial responses), and disease control rate (DCR; defined as
the rate of complete and partial responses and stable disease). The
following efficacy data were collected: median values of OS, PFS,
and TTP; hazard ratios of OS, PFS, and TTP; and RR and DCR.
The control arm in each trial was determined by the consensus of
three investigators (TM, YY, and TY) for randomised phase II
studies with selection designs wherein all arms were considered
experimental treatments.
Statistical analysis. The coefficient of determination (r2) was used
to evaluate correlations between the treatment effects on surrogate
efficacy end points and treatment effects on OS. Treatment effects
on OS were analysed using a linear regression model weighted
according to the study sample size of each trial. This model
included the treatment effect on each surrogate end point as an
exploratory variable. The precision levels of predictions based on
this model were demonstrated by 95% confidence intervals (CIs)
around the regression line. The treatment effects on PFS and OS
were analysed via conversion to a logarithmic scale. The ratios of
the median PFS, TTP, and OS between the control and
experimental arms in each trial were used to summarise treatment
effects because the hazard ratios (HRs) were not always reported.
For RR and DCR, the ratios between the control arm and
experimental arm were evaluated. TTP and failure-free survival
were reclassified as PFS (Schinzari et al, 2009; Sasaki et al, 2013).
A ratio of less than 1 denotes a favourable result for PFS, RR, DCR,
and OS in the experimental arm.
Several additional analyses, not pre-specified, were performed.
The correlations between treatment effects on surrogate efficacy
end points and treatment effects on OS among trials with
gemcitabine-containing therapies and with targeted agents were
analysed. Sensitivity analyses were also performed to support the
correlation observed between the median PFS ratios and median
OS ratios in all trials. The surrogate threshold effect (STE) on PFS
was calculated in all trials and subgroups. The STE is derived from
a vertical line that transects the upper 95% predictive limit and a
median OS ratio equal to 1; this represents the minimum PFS effect
that could predict a positive OS effect (Burzykowski and Buyse,
2006). The predicted median PFS ratio associated with a 20%
improvement in the median OS was calculated from the slope of
each regression line because an improvement in the median OS of
at least 20% has been generally agreed upon as a clinically
meaningful outcome improvement in cancer clinical trials (Ellis
et al, 2014). We used SAS software version 9.4 (SAS Institute Inc.,
Cary, NC, USA) for the statistical analyses.
RESULTS
Trials included in the analysis. Among the 426 retrieved papers/
abstracts, 17 randomised trials (14 phase II studies and 3 phase III
studies) with 36 treatment arms were identified (Figure 1 and
Table 1) (Kornek et al, 2004; Ducreux et al, 2005; Rao et al, 2005;
Schinzari et al, 2009; Okusaka et al, 2010; Sharma et al, 2010; Valle
et al, 2010; Lee et al, 2012; Kang et al, 2012; Morizane et al, 2013;
Sasaki et al, 2013; Malka et al, 2014; Moehler et al, 2014; Valle et al,
2014; Chen et al, 2015; Leone et al, 2015; Santoro et al, 2015).
A total of 2148 patients with 19 paired arms were analysed. PFS
was reported in 14 trials, and TTP was reported in 2 trials.
Although RR was reported in all trials, a best supportive care arm
in one trial reported no response (Sharma et al, 2010). DCR was
reported in 15 trials. Two trials were terminated early. A phase III
trial comparing 5-fluorouracil (5-FU)þ epirubicinþ leucovorin
with epirubicinþ cisplatinþ 5-FU and a phase II trial comparing
GPþ placebo with GPþ cediranib were closed because of poor
accrual and new drug development cessation, respectively (Rao
et al, 2005; Valle et al, 2014). The median values tended to favour
the experimental arms over the standard arms with respect to the
reported median PFS (5.8 months vs 4.9 months), median OS (10.1
months vs 9.5 months), RR (26.1% vs 15.5%), and DCR (71.7% vs
64.9%). A forest plot of the treatment effects on PFS and OS in
trials reporting HR is shown in Figure 2. The median HR also
tended to favour the experimental arms over the standard arms
with respect to the reported PFS (0.80) and OS (0.82). In trials with
targeted agents, however, the HRs for PFS and OS trended to
favour the control arms. The median PFS and OS for gemcitabine-
alone ranged widely from 3.7 to 5.0 months and 7.7 to 11.2
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months, respectively. The median PFS and OS for gemcitabineþ
platinum combination therapies also exhibited wide distributions
of 4.1–8.5 months and 9.5–12.4 months, respectively.
Correlation between treatment effects. Correlations between the
surrogate end points and OS are summarised in Table 2. The
median PFS ratio and OS ratio were moderately correlated
(r2¼ 0.66; 95% CI, 0.32–0.85, Po0.001; Figure 3A). The correla-
tion between the RR ratio and median OS ratio in all 17 trials with
17 paired arms was weak (r2¼ 0.29; 95% CI, 0.01–0.65, P¼ 0.021;
Figure 3B), as were the correlations between the DCR ratio and
median OS ratio in 15 trials with 17 paired arms (r2¼ 0.34; 95%
CI, 0.02–0.69, P¼ 0.011; Figure 3C).
Fourteen trials with gemcitabine-containing therapies were
identified, and correlations were analysed between the median
PFS ratio and OS ratio in 15 paired arms, RR ratio and median OS
ratio in 14 paired arms, and DCR ratio and median OS ratio in 14
paired arms. The median PFS ratio associated strongly with the
median OS ratio (r2¼ 0.78; 95% CI, 0.46–0.92, Po0.001;
Figure 4A). However, the correlations of the RR ratio and DCR
ratio with the median OS ratio were weak (Table 2). Only six trials
with targeted agents were identified, and correlations were
analysed between the seven paired arms of those end points and
the median OS ratios. The median PFS ratio associated strongly
with the median OS ratio (r2¼ 0.78; 95% CI, 0.14–0.96, P¼ 0.004;
Figure 4B), and this correlation was stronger than that observed
between the RR ratio and DCR ratio and the median OS ratio
(Table 2).
Sensitivity analysis. Several sensitivity analyses were performed to
support the strong correlations observed between the median PFS
ratio and median OS ratio in all trials (Table 2). When 10 trials
with total sample sizes ofo100 patients were excluded, an r2-value
of 0.60 (95% CI, 0.02–0.92, P¼ 0.015) was calculated between the
median PFS ratio and median OS ratio in 7 trials with 8 paired
arms. The r2-value was 0.64 (95% CI, 0.27–0.86, Po0.001) after
excluding 2 trials that ended early. Among the 8 trials with 9 paired
arms that reported HRs for both PFS and OS, the r2-value was 0.63
(95% CI, 0.07–0.91, P¼ 0.006). After excluding 3 trials that
reported TTP or failure-free survival, an r2-value of 0.62 (95% CI,
0.23–0.85, Po0.001) was calculated between the median PFS ratio
and median OS ratio in 14 trials with 16 paired arms.
Predicted treatment effect on PFS. The STE was 0.83 for all trials
(Figure 3A), 0.81 for trials with gemcitabine-containing therapies
(Figure 4A), and was not calculated for trials with targeted agents.
The predicted median PFS ratio associated with a 20% improve-
ment in the median OS was 0.71 for all trials, 0.69 for trials with
gemcitabine-containing therapies, and 0.40 for trials with targeted
agents.
DISCUSSION
Our analysis demonstrated that an improvement in PFS was
moderately associated with an improvement in OS in randomised
trials of first-line chemotherapy for ABTC. A strong correlation
between PFS and OS was confirmed in both subgroups of
gemcitabine-containing trials and targeted agent-combined trials,
which have been actively investigated in ABTC recently.
In the trials we analysed, the significant improvement in OS
with the significant improvement in PFS was observed in two
paired arms, which involved a comparison between GP and
gemcitabine in the ABC-02 trial and a comparison between
modified gemcitabineþ oxaliplatin and best supportive care
(Sharma et al, 2010; Valle et al, 2010). Particularly, the ABC-02
trial had the largest sample size. One of the reasons for our positive
results was that most analysed trials tended to have results similar
to those of the ABC-02 trial, although the slight improvement in
Full-text articles excluded
(n = 12)
Studies included in the analysis
(n = 17)
Records screened
(n = 390)
Records excluded
(n = 361)
Records after duplicates removed
(n = 390)
Records identified through PubMed
database searching
(n = 285)
Additional records (ASCO/Gastrointestinal Cancers
Symposium (n = 94) and ESMO/World Congress of
Gastrointestinal Cancer (n = 47))
(n = 141)
Full-text articles assessed
for eligibility
(n = 29)
• Phase II part of phase II/III trial (n = 1)
• Non-English article (n = 2)
• Information of trial concept (n = 4)
• Retrospective analysis (n = 1)
• No description of overall survival,
  progression-free survival, or time to
  progression (n = 2)
• Result combined with pancreatic and
  biliary tract cancers (n = 1)
• Subgroup analysis that are not stratified
  by tumour type (n = 1)
Figure 1. Study selection according to PRISMA (preferred reporting items for systemic reviews) diagram. Abbreviations: ASCO¼American
Society of Clinical Oncology; ESMO¼European Society of Medical Oncology.
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OS was not statistically significant. Furthermore, it was suggested
that the impact of the post-progression survival to OS was weak,
compared with the association between PFS and OS. The validity
of PFS as a surrogate end point for OS has been investigated in
various types of cancers, but remains controversial in some
(Burzykowski et al, 2008; Paoletti et al, 2013; Blumenthal et al,
2015; Johnson et al, 2015). The increased proportions of
subsequent treatments and crossovers, as well as prolonged OS
in recent cancer trials, might partly explain why the strong
correlation between PFS and OS was not detected in first-line trials.
The efficacy of subsequent treatment after the first progression has
not been established in ABTC, and indeed, only a few active drugs
are used as second-line chemotherapy for ABTC. The correlation
between PFS and OS in second-line chemotherapy for ABTC was
moderate and the evidence remains insufficient to recommend it in
a systematic review (Lamarca et al, 2014), although 15–80% of
Table 1. Characteristics of trials included in the analysis
Reference (year) Treatment arms Phase
No. of
patients
Primary
end point RR (%) DCR (%)
Median
PFS (months) HR (95% CI)
Median OS
(months) HR (95% CI)
Kornek et al (2004) C arm:
MMCþCAPE
II 26 RR 30.7 65.4 5.3 NR 9.3 NR
E arm:
MMCþGEM
25 20 56 4.2 6.7
Rao et al (2005) C arm: FELV III 27 OS 15 60 7.2a NR 12 NR
E arm: ECF 27 19.2 65.4 5.2a 9
Ducreux et al (2005) C arm: HDFU II 29 RR 7.1 NR 3.3 NR 5 NR
E arm: FLP 29 18.5 3.3 8
Schinzari et al (2009) C arm: FU/LV II 23 NR 21.7 56.5 2.7b NR 6.7 NR
E arm: FOLFOX4 25 28 72 5.0b 12.6
Sharma et al (2010) C arm: BSC II 27 OS 0 3.7 2.8 1 4.5 1
E arm: FUFA 28 14.3 21.4 3.5 0.72 (0.39–1.34) 4.6 0.82 (0.45–1.51)
E arm: mGEMOX 26 30.7 68.7 8.5 0.28 (0.14–0.56) 9.5 0.44 (0.22–0.86)
Okusaka et al (2010) C arm: GEM II 42 OS 11.5 50 3.7 0.66 (0.41–1.05) 7.7 0.69 (0.42–1.13)
E arm: GP 41 19.5 68.3 5.8 11.2
Valle et al (2010) C arm: GEM III 206 OS 15.5 71.8 5 0.63 (0.51–0.77) 8.1 0.64 (0.52–0.80)
E arm: GP 204 26.1 81.4 8 11.7
Kang et al (2012) C arm: SP II 47 PFS 23.8 85.7 5.4 0.85 (0.52–1.36) 9.9 0.72 (0.45–1.17)
E arm: GP 49 19.6 71.7 5.7 10.1
Lee et al (2012) C arm: GEMOX III 133 PFS 16 66 4.2 0.80 (0.61–1.03) 9.5 0.93 (0.69–1.25)
E arm: GEMOXþ
Erlotinib
135 30 66 5.8 9.5
Sasaki et al (2013) C arm: GEM II 32 RR 9.4 62.5 4.3b NR 9.2 NR
E arm: GEMþS-1 30 20 70 5.6b 8.9
Morizane et al (2013) C arm: S-1 II 50 OS 17.4 NR 4.2 0.44 (0.29–0.67) 9 0.86 (0.54–1.36)
E arm: GEMþS-1 51 36.4 7.1 12.5
Malka et al (2014) C arm: GEMOX II 74 PFS 23 64.9 5.5 1.08 (0.75–1.54) 12.4 NR
E arm: GEMOXþ
Cetuximab
76 23.6 81.6 6.1 11
Valle et al (2014) C arm:
GPþ Placebo
II 62 PFS 18.5 64.8 7.4 0.93 (0.65–1.35) 11.9 0.86 (0.58–1.27)
E arm:
GPþCediranib
62 44.1 78 8 14.1
Moehler et al (2014) C arm:
GEMþPlacebo
II 48 PFS 10 90 4.9 1.28 (0.81–2.02) 11.2 1.2 (0.75–1.93)
E arm:
GEMþSorafenib
49 14.3 85.7 3 8.4
Santoro et al (2015) C arm:
GEMþPlacebo
II 52 PFS 13.5 38.5 4.9 1 10.1 NR
E arm: Vandetanib 56 3.6 25 3.4 1.3 (0.86–1.96) 7.5
E arm: GEMþ
Vandetanib
57 19.3 29.8 3.7 1.3 (0.75–1.70) 9.3
Chen et al (2015) C arm: GEMOX II 60 RR 15 36.7 4.1 0.70 (0.48–1.01) 9.8 NR
E arm: GEMOXþ
Cetuximab
62 27.4 58.1 6.7 10.6
Leone et al (2015) C arm: GEMOX II 44 PFS 18.2 63.6 5.5 NR 9.9 NR
E arm: GEMOXþ
Panitumumab
45 24.4 73.3 7.7 9.5
Abbreviations: BSC¼best supportive care; C arm¼ control arm; CAPE¼ capecitabine; CI¼ confidence interval; DCR¼disease control rate; E arm¼ experimental arm; ECF¼ epirubicinþ
cisplatinþ 5-fluorouracil; 5-FU¼ 5-fluorouracil; FELV¼ 5-FUþ epirubicinþ leucovorin; FOLFOX4¼ infusional 5-FUþ leucovorinþoxaliplatin; FLP¼ 5-FUþ leucovorinþ cisplatin; FUFA¼
5-FUþ folic acid; FU/LV¼ 5-FUþ leucovorin; GEM¼gemcitabine; GEMOX; gemcitabineþoxaliplatin; GP¼gemcitabineþ cisplatin; HDFU¼ high-dose 5-FU; HR¼ hazard ratio; mGEMOX¼modified
gemcitabineþoxaliplatin; MMC¼mitomycin C; NR¼ not reported; OS¼overall survival; PFS¼progression-free survival; RR¼ response rate; SP¼ S-1þ cisplatin.
aFailure-free survival.
bTime to progression.
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patients received second-line chemotherapy in our analysed trials.
Thus, this might not affect the close correlation of PFS and OS in
the present study.
It is difficult to interpret whether a high correlation coefficient
of a parameter with a true end point is clinically meaningful as a
surrogate (Burzykowski and Buyse, 2006). The STE was introduced
as a concept, which was defined as the minimum treatment effect
on the surrogate necessary to predict a non-zero effect on the true
end point. In several studies that demonstrated a strong correlation
between PFS and OS, the STE on PFS exceeded 0.80 (Mauguen
et al, 2013; Paoletti et al, 2013; Sidhu et al, 2013). Our result is
similar, and the high surrogate thresholds were obtained both in all
trials (STE 0.83) and in trials with gemcitabine-containing
therapies (0.81). Therefore, PFS may be used as a surrogate end
point for OS in first-line chemotherapy for ABTC. However,
among trials with targeted agents, the STE on PFS could not be
calculated and the PFS did not appear to be a valid surrogate end
point for OS, despite its strong correlations with OS. The reason
for this discrepancy may be attributable to the small number of
trials and lack of a significant OS improvement in those trials.
According to the discussions recently held by working groups of
the ASCO Research Committee, an improvement in the median
OS of at least 20% was generally agreed upon as a clinically
meaningful improvement in the outcome of a cancer clinical trial
(Ellis et al, 2014). Using this benchmark of a minimum 20%
improvement in OS, the calculated median PFS ratio in our study
was B0.70. This value will become the targeted median PFS ratio
when planning a randomised clinical trial of ABTC treatment with
a superiority design.
This analysis did not reveal a strong correlation between RR and
OS or DCR and OS. Recent meta-analyses of other cancers also
failed to report strong correlations between these parameters
(Burzykowski et al, 2008; Sidhu et al, 2013; Blumenthal et al, 2015).
Some recent reports have described correlations between OS and
novel parameters such as changes in the tumour volume, depth of
response, and early tumour shrinkage in some types of cancers
Table 2. Weighted linear regression analyses of correlations between surrogate end points and OS
No. of patients
(paired arms) Intercept Slope r2 (95% CI) P-value
Median OS ratio vs median PFS ratio
All trials 2148 (19) 0.032 0.624 0.66 (0.32–0.85) o0.001
Trials with gemcitabine-containing therapies 1933 (15) 0.050 0.623 0.78 (0.46–0.92) o0.001
Trials with targeted agents 953 (7) 0.112 0.328 0.78 (0.14–0.96) 0.004
Median OS ratio vs RR ratio
All trials 2040 (17) 0.013 0.282 0.29 (0.01–0.65) 0.021
Trials with gemcitabine-containing therapies 1880 (14) 0.020 0.268 0.39 (0.02–0.75) 0.013
Trials with targeted agents 953 (7) 0.119 0.155 0.43 (0.03–0.89) 0.090
Median OS ratio vs DCR ratio
All trials 1989 (17)  0.038 0.227 0.34 (0.02–0.69) 0.011
Trials with gemcitabine-containing therapies 1832 (14)  0.037 0.293 0.60 (0.17–0.86) o0.001
Trials with targeted agents 953 (7) 0.094 0.312 0.44 (0.03–0.89) 0.086
Sensitivity analyses between PFS and OS
Trials reporting median PFS 1984 (16) 0.026 0.596 0.62 (0.23–0.85) o0.0001
Trials reporting both HRs for PFS and OSa 1287 (9)  0.075 0.528 0.63 (0.07–0.91) 0.006
Trials with total sample size X100 enroled patients 1392 (8) 0.037 0.597 0.60 (0.02–0.92) 0.015
Not early closed trials 1970 (17) 0.042 0.630 0.64 (0.27–0.86) o0.001
Abbreviations: CI¼ confidence interval; DCR¼disease control rate; HR¼ hazard ratio; OS¼overall survival; PFS¼progression-free survival; RR¼ response rate; r2¼ coefficient of determination.
aThe correlation between PFS HRs and OS HRs.
Reference (year)
Sharma (2010)
Sharma (2010)
Okusaka (2010)
Valle (2010)
Valle (2014)
Moehler (2014)
Santoro (2015)
Santoro (2015)
Chen (2015)
Kang (2012)
Lee (2012)
Morizane (2013)
Malka (2014)
E arm vs C arm
FUFA vs BSC
mGEMOX vs BSC
GP vs GEM
GP vs GEM
GP vs SP
GEMOX + Erlotinib vs GEMOX
GEMOX + Cetuximab vs GEMOX
GEMOX + Cetuximab vs GEMOX
GP + Cediranib vs GP + Placebo
GEM + Sorafenib vs GEM + Placebo
Vandetanib vs GEM + Placebo
GEM + Vandetanib vs GEM + Place
GEM + S-1 vs GEM
0.1 1 10 0.1 1 10
HR for PFS HR for OS
Favours E arm Favours C arm Favours E arm Favours C arm
Figure 2. A forest plot of treatment effects on progression-free survival (PFS) and overall survival (OS) in trials reporting hazard ratios (HRs).
Abbreviations: BSC¼best supportive care; C arm¼ control arm; CI¼ confidence interval; E arm¼ experimental arm; FUFA¼ 5-FUþ folic acid;
GEM¼gemcitabine; GEMOX¼gemcitabineþoxaliplatin; GP¼gemcitabineþ cisplatin; mGEMOX¼modified gemcitabineþoxaliplatin;
SP¼S-1þ cisplatin.
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(Jain et al, 2012; Petrelli et al, 2015; Sahani et al, 2015; Sharma et al,
2015; Venook and Tabernero, 2015). However, the usefulness of
those parameters as surrogate end points for OS remains unclear.
Our study has a few limitations. First, a majority of the main
trials included in this analysis were phase II trials. Only three
randomised phase III trials were included, one of which was closed
early because of poor accrual. The accuracy decreased in trials with
a small sample size. Therefore, we analysed trials with total sample
size of X100 patients and trials excluding early closed trials, and
confirmed that the correlations between PFS and OS were similar
to those reported in all trials. Second, the correlations between the
median PFS and OS ratios were analysed mainly because only a few
HRs were reported for OS and PFS. However, the correlation
between the reported HRs for PFS and reported HRs for OS was
similar to the results of the primary analysis. In addition, the HRs
for PFS and OS were found to be reasonably well-represented by
the ratios of the medians (Redman et al, 2013). Third, the tumour
locations varied among biliary tract cancer cases, and poorly visible
perihilar tumours, in which progression was difficult to assess,
were often included. These might explain the differences in efficacy
observed between trials. The reported median PFS and OS in our
analysed trials were uneven among the gemcitabine-alone arms
and among the gemcitabineþ platinum combination therapy
arms. Additional analysis involving the proportions of tumour
locations among trials might be needed in future. Finally, this study
was based on literature, and thus future analyses of individual
patient data are needed to confirm the strength of the correlation
in ABTC (Buyse et al, 2010). To validate our prediction externally,
we searched for eligible studies from March 2015 to January 2016.
Only two small randomised phase II trials, both of which were
presented as abstracts at the ASCO annual meeting 2015, were
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points and overall survival (OS) in all selected trials. (A) Correlation
between median progression-free survival (PFS) ratios and median OS
ratios. The point where the horizontal and vertical dotted line crosses
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median OS ratios and response rate (RR) ratios. (C) Correlation between
median OS ratios and disease control rate (DCR) ratios. Circle size is
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identified (Jensen et al, 2015; Vogel et al, 2015). These trials
included both gemcitabine-containing regimens and targeted
agents. The reported median OS ratios were 1.39 and 0.60; our
calculated OS ratios were 1.24 and 0.91, respectively. There were a
small number of trials for the external validation, and it should be
done in future.
In conclusion, we found a moderate correlation between PFS
and OS, and a relatively good STE value. Our regression model
could provide benchmarks to calculate the PFS in order to
demonstrate the clinically required improvement of OS. In patients
with ABTC, OS could easily be considered the primary end point
in a phase III trial, because the post-progression survival is short.
Accordingly, our results indicate that PFS is an appropriate end
point in a phase II trial of a newly developed drug.
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